Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

ChemMedChem

Volumn 7, Issue 8, 2012, Pages 1385-1403

  Bärfacker, Lars ^a   Kuhl, Alexander ^a   Hillisch, Alexander ^a   Grosser, Rolf ^a   Figueroa Pérez, Santiago ^a   Heckroth, Heike ^a   Nitsche, Adam ^a   Ergüden, Jens Kerim ^a   Gielen Haertwig, Heike ^a   Schlemmer, Karl Heinz ^a   Mittendorf, Joachim ^a   Paulsen, Holger ^a   Platzek, Johannes ^a   Kolkhof, Peter ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

BAY 94 8862; Cardiorenal disease; Heart failure; MR antagonists; Natriuresis

Indexed keywords

(3 ETHYLQUINOLIN 5 YL)METHANOL; 1 [2 HYDROXY 3 [PROP 1 EN 1 YL]PHENYL]ETHANONE; 2 [(3 ETHYLQUINOLIN 5 YL)METHYLENE] 3 OXOBUTANENITRILE; 2 CYANOETHYL 3 OXOBUTANOATE; 2 METHYL 8 [PROP 1 EN 1 YL] 4H CHROMEN 4 ONE; 3 ETHYLQUINOLINE 5 CARBALDEHYDE; 3 ETHYLQUINOLINE 5 CARBOXYLIC ACID; 4 (3 ETHYLQUINOLIN 5 YL) 2,6 DIMETHYL 5 (3 METHYLBUTANOYL) 1,4 DIHYDROPYRIDINE 3 CARBONITRILE; 4 (4 CYANO 2 METHOXYPHENYL) 2 METHYL 5 OXO 1,4,5,6 TETRAHYDRO 1,6 NAPHTHYRIDINE 3 CARBONITRILE; 4 CYANO 2 METHOXYPHENYL TRIFLUOROMETHANESULFONATE; 4 FORMYL 3 METHOXYBENZONITRILE; 4 HYDROXY 3 METHOXYBENZONITRILE; 9 OXO 9H FLUORENE 4 CARBALDEHYDE; BAY 94 8862; CYCLOBUTYL 3 AMINOBUT 2 ENOATE; CYCLOBUTYL 3 OXOBUTANOATE; CYCLOBUTYL 5 ACETYL 2,6 DIMETHYL 4 (2 METHYL 4 OXO 4H CHROMEN 8 YL) 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; ETHYL 2 [2 CYANO 1 (3 ETHYLQUINOLIN 5 YL) 3 OXOBUTYL] 1,3 DITHIOLANE 2 CARBOXYLATE; ETHYL 5 ACETYL 2,6 DIMETHYL 4 (2 METHYL 4 OXO 4H CHROMEN 8 YL) 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; ETHYL 5 CYANO 4 (3 ETHYLQUINOLIN 5 YL) 6 METHYL 1,4 DIHYDROPYRIDAZINE 3 CARBOXYLATE; ISOPROPYL 2 [(2 AMINOETHOXY)METHYL] 5 CYANO 4 (3 ETHYLQUINOLIN 5 YL) 6 METHYL 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; ISOPROPYL 3 AMINO 4 [2 (2,5 DIMETHYL 1H PYRROL 1 YL)ETHOXY]BUT 2 ENOATE; ISOPROPYL 4 [2 (2,5 DIMETHYL 1H PYRROL 1 YL)ETHOXY] 3 OXOBUTANOATE; ISOPROPYL 5 ACETYL 2,6 DIMETHYL 4 (2 METHYL 4 OXO 4H CHROMEN 8 YL) 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; ISOPROPYL 5 CYANO 2 [[2 (2,5 DIMETHYL 1H PYRROL 1 YL)ETHOXY] METHYL] 4 (3 ETHYLQUINOLIN 5 YL) 6 METHYL 1,4 DIHYDROPYRIDINE CARBOXYLATE; ISOPROPYL 5 CYANO 2,6 DIMETHYL 4 (9 OXO 9H FLUOREN 4 YL) 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; ISOPROPYL 5 CYANO 4 (3 ETHYLQUINOLIN 5 YL) 1,2,6 TRIMETHYL 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; NAPHTHYRIDINE DERIVATIVE; SODIUM 1 CYANOPROP 1 EN 2 OLATE; TERT BUTYL 3 (4 CYANO 2 METHOXYPHENYL)ACRYLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; IC 50; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; CHRONIC DISEASE; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HEART FAILURE; HUMANS; KIDNEY DISEASES; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; POTASSIUM; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, MINERALOCORTICOID; SODIUM;

EID: 84861554853     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201200081     Document Type: Article

References (57)

1. B. Pitt, F. Zannad, W. J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, J. Wittes, N. Engl. J. Med. 1999, 341, 709-717;
2. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin, N. Engl. J. Med. 2003, 348, 1309-1321;
3. F. Zannad, J. J. V. McMurray, H. Krum, D. J. vanVeldhuisen, K. Swedberg, H. Shi, J. Vincent, S. J. Pocock, B. Pitt, New Engl. J. Med. 2011, 364, 11-21.
4. A. Sato, K. Hayashi, M. Naruse, T. Saruta, Hypertension 2003, 41, 64-68;
5. A. H. van den Meiracker, R. G. Baggen, S. Pauli, A. Lindemans, A. G. Vulto, D. Poldermans, F. Boomsma, J. Hypertens. 2006, 24, 2285-2292;
6. J. P. Bertocchio, D. G. Warnock, F. Jaisser, Kidney Int. 2011, 79, 1051-1060.
7. J. Fagart, A. Hillisch, J. Huyet, L. Bärfacker, M. Fay, U. Pleiss, E. Pook, S. Schäfer, M.-E. Rafestin-Oblin, P. Kolkhof, J. Biol. Chem. 2010, 285, 29932-29940.
8. M. deGasparo, U. Joss, H. P. Ramjoue, S. E. Whitebread, H. Haenni, L. Schenkel, C. Kraehenbuehl, M. Biollaz, J. Grob, J. Schmidlin, P. Wieland, U. Wehrli, J. Pharmacol. Exp. Ther. 1987, 240, 650-656;
9. M. deGasparo, S. E. Whitebread, G. Preiswerk, X. Jeunemaître, P. Corvol, J. Ménard, J. Steroid Biochem. 1989, 32, 223-227.
10. S. M. Garthwaite, E. G. McMahon, Mol. Cell. Endocrinol. 2004, 217, 27-31;
11. X. Hu, S. Li, E. G. McMahon, D. S. Lala, A. E. Rudolph, Mini-Rev. Med. Chem. 2005, 5, 709-718.
12. M. H. Weinberger, B. Roniker, S. L. Krause, R. J. Weiss, Am. J. Hypertens. 2002, 15, 709-716;
13. H. K. Parthasarathy, J. Menard, W. B. White, W. F. Young, Jr., G. H. Williams, B. Williams, L. M. Ruilope, G. T. McInnes, J. M. Connell, T. M. MacDonald, J. Hypertens. 2011, 29, 980-990.
14. P. Kolkhof, S. A. Borden, Mol. Cell. Endocrinol. 2012, 350, 310-317.
15. For reviews see:
16. M. J. Meyers, X. Hu, Expert Opin. Ther. Pat. 2007, 17, 17-23;
17. "Nuclear Receptors as Targets in Cardiovascular Diseases": P. Kolkhof, L. Bärfacker, A. Hillisch, H. Haning, S. Schaefer in Nuclear Receptors as Drug Targets (Eds.: E. Ottow, H. Weinmann), Wiley-VCH, Berlin, 2008, pp.409-429. For more recent work see:
18. M. J. Meyers, G. B. Arhancet, S. L. Hockerman, X. Chen, S. A. Long, J. Med. Chem. 2010, 53, 5979-6002;
19. T. Hasui, N. Matsunaga, T. Ora, N. Ohyabu, N. Nishigaki, Y. Imura, Y. Igata, H. Matsui, T. Motoyaji, T. Tanaka, N. Habuka, S. Sogabe, M. Ono, C. S. Siedem, T. P. Tang, C. Gauthier, L. A. DeMeese, S. A. Boyd, S. Fukumoto, J. Med. Chem. 2011, 54, 8616-8631.
20. S. Goldmann, J. Stoltefuß, Angew. Chem. 1991, 103, 1587-1605; Angew. Chem. Int. Ed. Engl. 1991, 30, 1559-1577.
21. J.-K. Ergueden, P. Kolkhof, P. Sandner, A. Kuhl, J.-P. Stasch, E. Pook, K.-H. Schlemmer, Int. Pat. Appl. WO2005/087740, 2005; also see:
22. A. Kuhl, P. Kolkhof, H. Heckroth, K.-H. Schlemmer, I. Flamme, S. Figueroa-Perez, H. Gielen-Haertwig, R. Grosser, J.-K. Ergueden, D. Lang, US Pat. Appl. US20090214675, 2009;
23. A. Kuhl, P. Kolkhof, H. Heckroth, K.-H. Schlemmer, I. Flamme, S. Figueroa-Perez, H. Gielen-Haertwig, R. Grosser, J.-K. Ergueden, D. Lang, US Pat. Appl. US20100022484, 2010.
24. J. D. Dietz, S. Du, C. W. Bolton, M. A. Payne, C. Xia, J. R. Blinn, J. W. Funder, X. Hu, Hypertension 2008, 51, 742-748;
25. G. B. Arhancet, S. S. Woodard, J. D. Dietz, D. J. Garland, G. M. Wagner, K. Iyanar, J. T. Collins, J. R. Blinn, R. E. Numann, X. Hu, H.-C. Huang, J. Med. Chem. 2010, 53, 4300-5304;
26. G. B. Arhancet, S. S. Woodard, K. Iyanar, B. L. Case, R. Woerndle, J. D. Dietz, D. J. Garland, J. T. Collins, M. A. Payne, J. R. Blinn, S. I. Pomposiello, X. Hu, M. I. Heron, H.-C. Huang, L. F. Lee, J. Med. Chem. 2010, 53, 5970-5978;
27. P.-Y. Michellys, W. Pei, J. Wityak, Int. Pat. Appl. WO2006/066011, 2006;
28. S. Fukumoto, T. Ohra, J. Sakamoto, H. Takashima, Int. Pat. Appl. WO2005/097118, 2005.
29. F. J. Ehlert, W. R. Roeske, E. Itoga, H. I. Yamamura, Life Sci. 1982, 30, 2191-2202.
30. R. A. Burges, M. G. Dodd, D. G. Gardiner, Am. J. Cardiol. 1989, 64, I10-I20.
31. For bicalutamide see:
32. B. J. Furr, H. Tucker, Urology 1996, 47, 13-25; For tanaproget see:
33. Z. Zhang, A. M. Olland, Y. Zhu, J. Cohen, T. Berrodin, S. Chippari, C. Appavu, S. Li, J. Wilhem, R. Chopra, A. Fensome, P. Zhang, J. Wrobel, R. J. Unwalla, C. R. Lyttle, R. C. Winneker, J. Biol. Chem. 2005, 280, 28468-28475.
34. P. J. Fuller, Y. Yao, J. Yang, M. J. Young, J. Endocrinol. 2012, 213, 15-24;
35. M. L. Hultman, N. V. Krasnoperova, S. Li, S. Du, C. Xia, J. D. Dietz, D. S. Lala, D. J. Welsch, X. Hu, Mol. Endocrinol. 2005, 19, 1460-1473.
36. A. Hantzsch, Justus Liebigs Ann. Chem. 1882, 215, 1-82. For a more recent review see:
37. A. E. Sausins, G. Duburs, Chem. Heterocycl. Compd. 1992, 28, 363-391.
38. M. N. Alberti, G. C. Vongioukalakies, M. Orfanopoulos, J. Org. Chem. 2009, 74, 7274-7282.
39. T. Watanabe, F. Hamaguchi, S. Ohki, Chem. Pharm. Bull. 1972, 20, 2123-2127.
40. J. Stoltefuß, US Pat. US5476940, 1995.
41. C. Kashima, Y. Yamamoto, Bull. Chem. Soc. Jpn. 1979, 52, 1735-1737.
42. M. D. Taylor, K. R. Anderson, E. W. Badger, J. Heterocycl. Chem. 1989, 26, 1353-1356.
43. M. Weitzberg, R. Burch, B. Shearer, US Pat. US5079260, 1992.
44. W.-H. Cheung, S. L. Zheng, W. Y. Yu, G. C. Zhu, C.-M. Che, Org Lett. 2003, 5, 2535-2538.
45. For an application in formic acid see: F. Rancati, S. M. Bromidge, S. DelSordo, S. LaRosa, C. Parini, S. Gagliardi, Synth. Commun. 2008, 38, 2507-2520.
46. C. H. Nguyen, E. Bisagni, Synthesis 1984, 765-766.
47. Y. L. Janin, J. Chiki, M. Legraverend, C. Huel, E. Bisagni, Tetrahedron 1999, 55, 12797-12804;
48. I. I. Barabanov, L. G. Fedenok, M. S. Shvartsberg, Russ. Chem. Bull. 1998, 47, 2256-2261.
49. G. Franckowiak, U. Rosentreter, E. Perzborn, F. Seuter, M. Kayser, G. Thomas, US Pat. US4876255, 1989;
50. K. Cooper, M. J. Fray, M. J. Parry, K. Richardson, J. Steele, J. Med. Chem. 1992, 35, 3115-3129;
51. D. Nagarathnam, J. M. Wetzel, S. W. Miao, M. R. Marzabadi, G. Chiu, J. Med. Chem. 1998, 41, 5320-5333.
52. C. J. Bennett, S. T. Caldwell, D. B. McPhail, P. C. Morrice, C. G. Dhutie, R. C. Hartley, Bioorg. Med. Chem. 2004, 12, 2079-2098.
53. R. E. Ford, P. Knowles, E. Lunt, S. M. Marshall, A. J. Penrose, J. Med. Chem. 1986, 29, 538-549.
54. J. Huyet, G. M. Pinon, M. R. Fay, J. Fagart, M. E. Rafestin-Oblin, Mol. Pharmacol. 2007, 72, 563-571.
55. Y. Li, K. Suino, J. Daugherty, H. E. Xu, Mol. Cell 2005, 19, 367-380.
56. R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, P. S. Shenkin, J. Med. Chem. 2004, 47, 1739-1749.
57. W. L. Jorgensen, D. S. Maxwell, J. Tirado-Rives, J. Am. Chem. Soc. 1996, 118, 11225-11236.